Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

Recruiting now · Phase 2

Conditions studied: Cystic Fibrosis, CFTR Gene Mutation

In brief

ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.

Key facts

Study ID

NCT06747858

Run by

Arcturus Therapeutics, Inc.

People needed

33

Starts

2024-12-12

Expected to finish

2027-06-01

Last updated by the study team

2026-05-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• History of illness or medical condition that might pose an additional risk or may confound study results
• Recent moderate or severe hemoptysis
• Recent major surgery
• Solid organ or hematologic transplant
• Requirement of supplemental oxygen while awake or > 2L per minute while sleeping.
• Chronic maintenance systemic corticosteroids exceeding equivalent of daily 15 mg oral prednisone or 30 mg every other day
• Adequate liver and kidney function as determined by lab tests

Where it is running

• Seattle Children's Hospital — Seattle, Washington, United States (enrolling)
• University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States (enrolling)
• Children's Hospital of Los Angeles — Los Angeles, California, United States (enrolling)
• UT Health San Antonio — San Antonio, Texas, United States (enrolling)
• University of Arizona — Tucson, Arizona, United States (enrolling)
• Joe DiMaggio Children's Hospital — Hollywood, Florida, United States (enrolling)
• Boston Children's Hospital — Boston, Massachusetts, United States (enrolling)
• Washington University School of Medicine — St Louis, Missouri, United States (enrolling)
• Cleveland Clinic Foundation — Cleveland, Ohio, United States (enrolling)
• Medical University of South Carolina — Charleston, South Carolina, United States (enrolling)
• Vanderbilt University Medical Center — Nashville, Tennessee, United States (enrolling)
• Children's National Hospital — Washington D.C., District of Columbia, United States
• The Cystic Fibrosis Institute — Northfield, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.